Sportradar's Strong 2025 Earnings and Aggressive Buyback Mask Lingering Integration and Legal Risks

What happened

Sportradar reported full-year 2025 revenue growth of 17% to €1.29 billion, with adjusted EBITDA margin expanding 291 basis points to 23.0% and free cash flow reaching €167 million. The company announced a significant increase in its share repurchase authorization from $300 million to $1 billion, following $91 million in buybacks in 2025. These results come after the completion of the IMG ARENA acquisition, which management touts as key to future growth and margin expansion. However, DeepValue analysis warns that thin IFRS profitability, rights-related expense gravity, and ongoing antitrust litigation (PANDA) remain critical overhangs. Investors must now scrutinize whether the strong 2025 performance translates into sustainable 2026 synergy capture without additional rights 'repair' payments or legal setbacks.

Implication

The 2025 results, particularly the 33% adjusted EBITDA growth to €297 million, align with DeepValue's base scenario of margin expansion, reinforcing management's preview of +23% to +25% 2026 revenue growth and ~250 bps margin gains. However, the $1 billion buyback authorization, while signaling confidence, reduces financial flexibility amid €142.2 million in commitments for unlicensed rights and potential IMG contract 'repairs', echoing the $122 million prepayment at deal close. Investors should view the repurchase as a positive capital allocation move only if early 2026 results confirm IMG integration is margin-accretive without incremental costs. Critical monitoring points include updates on the PANDA antitrust litigation, which seeks an injunction that could impair bundling economics, and remediation of the material weakness in internal controls. Ultimately, the stock's risk-reward remains tilted toward proof from 2026 performance, as cash outflows for buybacks could strain the balance sheet if rights or litigation risks escalate.

Thesis delta

The thesis remains a 'Potential Buy' but with no material shift, as strong 2025 metrics validate the margin expansion narrative without resolving core risks. The expanded buyback introduces capital allocation uncertainty that could pressure the balance sheet if IMG integration requires additional payments or litigation outcomes worsen. Investors should maintain a cautious stance, awaiting 2026 guidance confirmation and evidence that rights economics are turning profitable rather than draining cash.